Osteoprotegerin Predicts Long-Term Outcome in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention | Zendy

Sune Pedersen | Zendy; Rasmus Møgelvang | Zendy; Mette Bjerre | Zendy; Jan Frystyk | Zendy; Allan Flyvbjerg | Zendy; Søren Galatius | Zendy; Tor BieringSørensen | Zendy; Allan Iversen | Zendy; Anders Hvelplund | Zendy; Jan Skov Jensen | Zendy

Open Access

Osteoprotegerin Predicts Long-Term Outcome in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

Author(s) -

Sune Pedersen,

Rasmus Møgelvang,

Mette Bjerre,

Jan Frystyk,

Allan Flyvbjerg,

Søren Galatius,

Tor BieringSørensen,

Allan Iversen,

Anders Hvelplund,

Jan Skov Jensen

Publication year - 2012

Publication title -

cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.547

H-Index - 63

eISSN - 1421-9751

pISSN - 0008-6312

DOI - 10.1159/000339880

Subject(s) - medicine , myocardial infarction , percutaneous coronary intervention , cardiology , interquartile range , heart failure , quartile , proportional hazards model , confidence interval

Osteoprotegerin (OPG) is a glycoprotein with a regulatory role in immune, skeletal and vascular systems. Data suggest that high circulating OPG levels are associated with an increased risk of cardiovascular disease. We analyzed the association between OPG and long-term outcome in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research